{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:40:10Z","timestamp":1787784010652,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.vaccine.2006.02.034","type":"journal-article","created":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T12:24:30Z","timestamp":1141388670000},"page":"3909-3920","source":"Crossref","is-referenced-by-count":60,"title":["Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis"],"prefix":"10.1016","volume":"24","author":[{"given":"E.","family":"Oliveira-Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Borja-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.O.P.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.W.","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Palatnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.B.","family":"Palatnik-de-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.02.034_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2006.02.034_bib2","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1016\/S0264-410X(03)00527-9","article-title":"Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine","volume":"21","author":"Santos","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0264-410X(00)00339-X","article-title":"A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante, RN)","volume":"19","author":"da Silva","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib4","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib5","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1016\/j.vaccine.2005.05.011","article-title":"Leishmune\u00ae vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs","volume":"23","author":"Nogueira","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune\u00ae) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4269\/ajtmh.1995.52.287","article-title":"Control of zoonotic visceral leishmaniasis. Is it time to change strategies?","volume":"52","author":"Tesh","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.02.034_bib8","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective Immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib9","series-title":"Proceedings of the Third World Congress on Leishmaniosis (Worldleish III)","first-page":"116","article-title":"Phase I safety and immunogenicity trial of Leishmune\u00ae in dogs of Brazilian endemic areas","author":"Borja Cabrera","year":"2005"},{"issue":"19","key":"10.1016\/j.vaccine.2006.02.034_bib10","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.01.072","article-title":"Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins","volume":"22","author":"Palatnik-de-Sousa","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2006.02.034_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.02.034_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-6215(95)00278-2","article-title":"Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy","volume":"280","author":"Jacobsen","year":"1996","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2006.02.034_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0031-9422(00)81518-6","article-title":"Structure of deacylsaponins obtained from the bark of Quillaja saponaria","volume":"26","author":"Higuchi","year":"1987","journal-title":"Phytochemistry"},{"key":"10.1016\/j.vaccine.2006.02.034_bib15","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/S0031-9422(00)84718-4","article-title":"Structures of compounds derived from the acyl moieties of quillajasaponin","volume":"26","author":"Higuchi","year":"1987","journal-title":"Phytochemistry"},{"key":"10.1016\/j.vaccine.2006.02.034_bib16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/0031-9422(88)80295-4","article-title":"An acylated triterpenoid saponin from Quillaja saponaria","volume":"27","author":"Higuchi","year":"1988","journal-title":"Phytochemistry"},{"key":"10.1016\/j.vaccine.2006.02.034_bib17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0031-9422(99)00422-7","article-title":"Triterpenoid saponins containing an acetylated branched d-fucosyl residue from Quillaja saponaria Molina","volume":"53","author":"Guo","year":"2000","journal-title":"Phyotchemistry"},{"key":"10.1016\/j.vaccine.2006.02.034_bib18","first-page":"119","article-title":"Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice","volume":"30","author":"Bradley","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2006.02.034_bib19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.57.3.754-763.1989","article-title":"Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate","volume":"57","author":"Palatnik","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.02.034_bib20","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the fucose mannose ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2006.02.034_bib21","first-page":"290","article-title":"The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"Ci\u00eancia e Cultura (J Braz Assoc Adv Sci)"},{"key":"10.1016\/j.vaccine.2006.02.034_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mossman","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2006.02.034_bib23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1086\/315871","article-title":"Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes","volume":"182","author":"Nardin","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.02.034_bib24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans","volume":"19","author":"Evans","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib25","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/S0264-410X(02)00209-8","article-title":"QS-21 structure\/function studies: effect of acylation on adjuvant activity","volume":"20","author":"Liu","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0264-410X(95)00077-E","article-title":"Structure\/function studies of QS21 adjuvant: assessment of triterpen-aldehyde and glucuronic acid roles in adjuvant function","volume":"13","author":"Soltysik","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.02.034_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0167-5699(96)10050-5","article-title":"Covalent chemical events in immune induction: fundamental and therapeutics aspects","volume":"17","author":"Rhodes","year":"1996","journal-title":"Immunol Today"},{"key":"10.1016\/j.vaccine.2006.02.034_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1567-5769(01)00016-9","article-title":"Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins","volume":"1","author":"Marciani","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2006.02.034_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/js9503136","article-title":"Isomerization and formulation stability of the vaccine adjuvant QS-21","volume":"85","author":"Cleland","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2006.02.034_bib30","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1021\/ac980365q","article-title":"Multiple-stage tandem mass spectrometry for structural characterization of saponins","author":"Van Setten","year":"1998","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2006.02.034_bib31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/js9504651","article-title":"Structure\u2013function relationship among Quillaja saponins serving as excipient for nasal and ocular delivery of insulin","volume":"85","author":"Pillion","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2006.02.034_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1567-5769(01)00016-9","article-title":"Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins","volume":"1","author":"Marciani","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2006.02.034_bib33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1248\/yakushi.123.957","article-title":"The effects of protein stabilizers on aggregation induced by multiple stress","volume":"123","author":"Arakawa","year":"2003","journal-title":"Yahukagu Zasshi"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T17:15:28Z","timestamp":1683393328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06002088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0264410X06002088"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.02.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}